Linked Data API

Show Search Form

Search Results

1002678
registered interest false more like this
date less than 2018-11-06more like thismore than 2018-11-06
answering body
Home Office more like this
answering dept id 1 more like this
answering dept short name Home Office more like this
answering dept sort name Home Office more like this
hansard heading Cannabis: Medical Treatments more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for the Home Department, if he will publish the advice used to inform his Department on the requirements that (a) the decision to prescribe medicinal cannabis products must be made by a specialist doctor and (b) medicinal cannabis products may only be prescribed when the patient has an unmet special clinical need that cannot be met by other treatments. more like this
tabling member constituency North Norfolk more like this
tabling member printed
Norman Lamb remove filter
uin 188750 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-11-12more like thismore than 2018-11-12
answer text <p>The prescription of these products by doctors on the Specialist Register of the General Medical Council (GMC) and only where there is an unmet clinical need follows the principles used by the Interim Expert Panel on cannabis-based products for medicinal use. This approach was agreed by senior clinicians on the Expert Panel, Chaired by Dr Michael McBride, Chief Medical Officer for Northern Ireland. This approach was subsequently supported by the Advisory Council on the Misuse of Drugs (ACMD) in their advice to the Home Secretary on rescheduling cannabis. The ACMD advice has been published and is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/further-advice-on-scheduling-of-cannabis-derived-medicinal-products" target="_blank">https://www.gov.uk/government/publications/further-advice-on-scheduling-of-cannabis-derived-medicinal-products</a></p><p>Any unlicensed medicines, including cannabis-based products for medicinal use, will be supplied under long-standing arrangements for the supply of what are known, in healthcare settings, as ‘specials’. This process is underpinned by the Human Medicines Act and, outside of clinical trials, only allows these unlicensed medicines to be prescribed where there is an unmet clinical need. This restriction is in place because unlicensed medicines have not been through the same quality, safety and efficacy tests as licenced medicines.</p>
answering member constituency Ruislip, Northwood and Pinner more like this
answering member printed Mr Nick Hurd more like this
question first answered
less than 2018-11-12T17:05:51.537Zmore like thismore than 2018-11-12T17:05:51.537Z
answering member
1561
label Biography information for Mr Nick Hurd more like this
tabling member
1439
label Biography information for Norman Lamb more like this